Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Veriheal

AUGUST 24, 2022

Any sales of psychedelic compounds would still be strictly prohibited; however, the initiative would allow for people to offer psychedelic services such as guidance and therapy or for harm reduction or spiritual purposes with or without payment. Not all alternative medicine advocates are in support of the Natural Medicine Health Act, however.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

AUGUST 23, 2021

Abernethy said, “We [FDA] remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety.”. She acknowledged that “FDA is considering the possibility of new legal pathways for CBD products.”.

Pets 105

Pets Hemp CBD Food 105

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 59

Marijuana Therapy Data THC 59

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). The first is legislative.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Sensi Seeds

NOVEMBER 28, 2018

Then, a blog post circulated online, notifying the industry that Spain’s food and safety authority, AECOSAN, had updated its legislation to prohibit the sale and distribution of products containing CBD being sold as food supplements. In August 2018, reports of shops being raided and CBD product confiscated began to circulate on Twitter.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. 1 Related Stories What’s the deal with ketamine? 1 Related Stories What’s the deal with ketamine?

Therapy 78

Therapy Access Blood Pressure Treatment 78

Veriheal

FEBRUARY 1, 2021

The filing is backed by MAPS (Multidisciplinary Association for Psychedelic Studies) and calls on the DEA to answer a four-year-old filing requesting approval of his application to become a federally registered marijuana cultivator. Back in 2016, the DEA said they were starting the process of approving “additional marijuana cultivators.”

DEA 63

DEA Therapy Cultivation Media 63

Veriheal

FEBRUARY 23, 2024

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.

DEA 99

DEA Chronic Pain Treatment Therapy 99

SMPL

FEBRUARY 11, 2020

“FDA is aware that companies market products containing cannabis and cannabis-derived compounds in ways that violate the law and may put consumer health and safety at risk.”. Questions remain regarding the safety of these compounds,” it continued. Trump included a similar request in prior budgets , but Congress rejected the cuts.

Research and Development 40

Research and Development Legalization Marijuana Programs 40